Cathepsin Activatable Fluorescent Probe

Breast Cancer Clinical Trial

— LUM015  

Official title:

A Phase I Study of the Safety and Activation of a Cathepsin-Activatable Fluorescent Cancer Specific Probe LUM015

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01626066
• Other study ID #: Pro00035444
• Status: Completed
• Phase: Phase 1
• First received: June 20, 2012
• Last updated: December 8, 2015
• Start date: June 2012
• Est. completion date: August 2015

Study information

• Verified date: December 2015
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Real-time detection of cancer cells during surgical removal of a tumor is important. Currently when tissue is removed at the time of surgery, the removed tissue goes to pathology when the margins (edges of the tissue) are examined to see if cancer cells are present. This may take a few to several days. Patients tissue with positive (cancer cells present) margins may require additional therapies including surgery. The purpose of this study is to determine a safe dose of a new imaging agent (LUM015), like a fluorescent contrast agent or dye, that will show in the tumor area during surgery and may help facilitate visualization of tumor for its removal.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: August 2015
• Est. primary completion date: August 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 74 Years

Eligibility

Inclusion Criteria:

• 18 years of age or older

• Diagnosis of soft tissue sarcoma and breast cancer patients scheduled for a lumpectomy or mastectomy.

• Subjects must be scheduled for surgical resection of a tumor at least 1 cm in size.

• Performance status of 0 or 1

• Able to read, understand and sign an informed consent form

• Must be able and willing to follow study procedures and instructions including a possible overnight stay before surgery

• Otherwise healthy except for the diagnosis of cancer

• ALT, AST, and total bilirubin within 1.5x institutional upper normal limits; and alkaline phosphatase within 2.5x institutional upper normal limits

• Serum creatinine of 1.5 mg or less; creatinine clearance greater than 30 ml/min

• May have previously received pre-operative external beam radiation therapy for this sarcoma

Exclusion Criteria:

• Pregnant or lactating

• Prolonged QT interval: corrected QT interval (QTc) > 480 msec

• Insulin dependent diabetes

• History of anaphylactic reactions to any drug or contrast agent

• Asthma under medical management

• Uncontrolled high blood pressure

• Severe, active co-morbidity

• Known substance addiction

• Sexually active and not willing/able to use medically acceptable forms of contraception.

• Obesity defined as BMI as body mass index greater than 35 kg/meter squared.

• Atopy or atopic syndrome

• Known AIDS

• Cannot have taken an investigational drug within 30 days of coming onto this study

Study Design

Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Breast Cancer
• Sarcoma
• Soft Tissue Sarcoma

Intervention

Drug:
• LUM015
LUM015 assigned dose given once by IV push

Locations

Country	Name	City	State
United States	Duke University Medical Center	Durham	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
David Kirsch	American Society of Clinical Oncology

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose of LUM015 in mg	Dose of LUM015 in mg that is tolerated and labels tumors	24 hours	Yes
Secondary	Mean number of fluorescence counts per second per square centimeter		At time of surgery	No
Secondary	To obtain PK/PD information regarding LUM015 when administered IV in patients.	The pharmacokinetic parameters to be measured will include: area under the curve (AUCt), maximum concentration (Cmax), time to maximum concentration (tmax) and first-order terminal (elimination) rate constant. Secondary (derived) parameters will include: terminal half-life (t1/2), clearance (CL), mean residence time (MRT), and apparent volume of distribution during the terminal phase (Vz). The distribution of these parameters will be described for each dose cohort separately; breast and sarcoma patients will be combined.	Two years	No
Secondary	To analyze cathepsin protease expression in tumors.	Cathepsin expression in tumors, measured in arbitrary units by Real-Time PCR compared to adjacent normal tissue when available, will be assessed in sarcomas and breast tumors. For each tissue specimen the expression of cathepsin will be compared to the imaging signal. Scatterplots of cathepsin level against imaging signal will be made according to tissue type within each dose cohort.	2 Years	No